Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has issued an announcement.
Zydus Lifesciences Limited has announced that it received an Establishment Inspection Report (EIR) from the USFDA for its oncology injectable facility in SEZ1, Ahmedabad. The facility’s classification has been upgraded from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI), reflecting improvements in compliance and potentially enhancing the company’s reputation and operational capabilities in the pharmaceutical industry.
More about Zydus Lifesciences Limited
Zydus Lifesciences Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of healthcare products, including oncology injectables. The company is known for its commitment to innovation and quality in the healthcare sector, catering to both domestic and international markets.
Average Trading Volume: 49,609
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1043.5B INR
For a thorough assessment of ZYDUSLIFE stock, go to TipRanks’ Stock Analysis page.